Clinical Development
Lovaxin SCCE
Ovarian & Pancreatic Cancer
Advaxis has entered into a research agreement to develop a construct to treat ovarian cancer based upon the antigen Stratum Corneum Chymotryptic Enzyme (SCCE). This marker has been found to be significantly elevated in both ovarian and pancreatic cancers, thus providing a therapeutic target for ovarian cancer.